Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.

Shares of Replimune Group REPL have surged 131.1% over the past three months, fueled by positive regulatory updates. In October, the FDA accepted the resubmission of the biologics license application ...

On Monday, Replimune Group Inc. (NASDAQ:REPL) is reeling after the FDA unexpectedly rejected its skin cancer treatment, triggering a stock plunge and a wave of investor outrage. Shares fell sharply ...

No matter whether you are a seasoned programmer or you simply want to take your first steps in writing code, Repl.it wants to help you get from idea to result as fast as possible — without complicated ...

HENLEY-IN-ARDEN, United Kingdom and DALLAS, Jan. 10, 2020 /PRNewswire/ -- Global retail IT consultancy and technology firm, REPL Group has successfully rolled out JDA Workforce Management to help ...

Replimune Group, Inc. REPL announced positive top-line results from the primary analysis of the IGNYTE study on lead pipeline candidate RP1, in combination with Bristol Myers’ BMY blockbuster ...

We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday. Replimune extended losses to a second consecutive day on ...